1
|
Shahiwala AF, Khan GA. Potential Phytochemicals for Prevention of Familial Breast Cancer with BRCA Mutations. Curr Drug Targets 2023; 24:521-531. [PMID: 36918779 DOI: 10.2174/1389450124666230314110800] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/08/2022] [Revised: 10/17/2022] [Accepted: 01/12/2023] [Indexed: 03/16/2023]
Abstract
Breast cancer has remained a global challenge and the second leading cause of cancer mortality in women and family history. Hereditary factors are some of the major risk factors associated with breast cancer. Out of total breast cancer cases, 5-10% account only for familial breast cancer, and nearly 50% of all hereditary breast cancer are due to BRCA1/BRCA2 germline mutations. BRCA1/2 mutations play an important role not only in determining the clinical prognosis of breast cancer but also in the survival curves. Since this risk factor is known, a significant amount of the healthcare burden can be reduced by taking preventive measures among people with a known history of familial breast cancer. There is increasing evidence that phytochemicals of nutrients and supplements help in the prevention and cure of BRCA-related cancers by different mechanisms such as limiting DNA damage, altering estrogen metabolism, or upregulating expression of the normal BRCA allele, and ultimately enhancing DNA repair. This manuscript reviews different approaches used to identify potential phytochemicals to mitigate the risk of familial breast cancer with BRCA mutations. The findings of this review can be extended for the prevention and cure of any BRCAmutated cancer after proper experimental and clinical validation of the data.
Collapse
Affiliation(s)
| | - Gazala Afreen Khan
- Department of Clinical Pharmacy & Pharmacotherapeutics, Dubai Pharmacy College for Girls, Dubai, United Arab Emirates
| |
Collapse
|
2
|
Tommasi C, Pellegrino B, Boggiani D, Sikokis A, Michiara M, Uliana V, Bortesi B, Bonatti F, Mozzoni P, Pinelli S, Squadrilli A, Viani MV, Cassi D, Maglietta G, Meleti M, Musolino A. Biological Role and Clinical Implications of microRNAs in BRCA Mutation Carriers. Front Oncol 2021; 11:700853. [PMID: 34552867 PMCID: PMC8450578 DOI: 10.3389/fonc.2021.700853] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/27/2021] [Accepted: 08/20/2021] [Indexed: 12/20/2022] Open
Abstract
Women with pathogenic germline mutations in BRCA1 and BRCA2 genes have an increased risk to develop breast and ovarian cancer. There is, however, a high interpersonal variability in the modality and timing of tumor onset in those subjects, thus suggesting a potential role of other individual’s genetic, epigenetic, and environmental risk factors in modulating the penetrance of BRCA mutations. MicroRNAs (miRNAs) are small noncoding RNAs that can modulate the expression of several genes involved in cancer initiation and progression. MiRNAs are dysregulated at all stages of breast cancer and although they are accessible and evaluable, a standardized method for miRNA assessment is needed to ensure comparable data analysis and accuracy of results. The aim of this review was to highlight the role of miRNAs as potential biological markers for BRCA mutation carriers. In particular, biological and clinical implications of a link between lifestyle and nutritional modifiable factors, miRNA expression and germline BRCA1 and BRCA2 mutations are discussed with the knowledge of the best available scientific evidence.
Collapse
Affiliation(s)
- Chiara Tommasi
- Medical Oncology and Breast Unit, University Hospital of Parma, Parma, Italy.,Department of Medicine and Surgery, University of Parma, Parma, Italy.,GOIRC (Gruppo Oncologico Italiano di Ricerca Clinica), Parma, Italy
| | - Benedetta Pellegrino
- Medical Oncology and Breast Unit, University Hospital of Parma, Parma, Italy.,Department of Medicine and Surgery, University of Parma, Parma, Italy.,GOIRC (Gruppo Oncologico Italiano di Ricerca Clinica), Parma, Italy
| | - Daniela Boggiani
- Medical Oncology and Breast Unit, University Hospital of Parma, Parma, Italy.,GOIRC (Gruppo Oncologico Italiano di Ricerca Clinica), Parma, Italy
| | - Angelica Sikokis
- Medical Oncology and Breast Unit, University Hospital of Parma, Parma, Italy.,GOIRC (Gruppo Oncologico Italiano di Ricerca Clinica), Parma, Italy
| | - Maria Michiara
- Medical Oncology and Breast Unit, University Hospital of Parma, Parma, Italy
| | - Vera Uliana
- Medical Genetics Unit, University Hospital of Parma, Parma, Italy
| | - Beatrice Bortesi
- Medical Oncology and Breast Unit, University Hospital of Parma, Parma, Italy.,GOIRC (Gruppo Oncologico Italiano di Ricerca Clinica), Parma, Italy
| | - Francesco Bonatti
- Medical Oncology and Breast Unit, University Hospital of Parma, Parma, Italy
| | - Paola Mozzoni
- Department of Medicine and Surgery, University of Parma, Parma, Italy
| | - Silvana Pinelli
- Department of Medicine and Surgery, University of Parma, Parma, Italy
| | - Anna Squadrilli
- Medical Oncology and Breast Unit, University Hospital of Parma, Parma, Italy
| | - Maria Vittoria Viani
- Dental School, Department of Medicine and Surgery, University of Parma, Parma, Italy
| | - Diana Cassi
- Unit of Dentistry and Oral-Maxillo-Facial Surgery, Surgical, Medical and Dental Department of Morphological Sciences related to Transplant, Oncology and Regenerative Medicine, University of Modena and Reggio Emilia, Modena, Italy
| | - Giuseppe Maglietta
- GOIRC (Gruppo Oncologico Italiano di Ricerca Clinica), Parma, Italy.,Research and Innovation Unit, University Hospital of Parma, Parma, Italy
| | - Marco Meleti
- Dental School, Department of Medicine and Surgery, University of Parma, Parma, Italy
| | - Antonino Musolino
- Medical Oncology and Breast Unit, University Hospital of Parma, Parma, Italy.,Department of Medicine and Surgery, University of Parma, Parma, Italy.,GOIRC (Gruppo Oncologico Italiano di Ricerca Clinica), Parma, Italy
| |
Collapse
|
3
|
Marciniak W, Matoušek T, Domchek S, Paradiso A, Patruno M, Irmejs A, Roderte I, Derkacz R, Baszuk P, Kuświk M, Cybulski C, Huzarski T, Gronwald J, Dębniak T, Falco M, Lener MR, Jakubowska A, Pullella K, Kotsopoulos J, Narod S, Lubiński J. Blood Arsenic Levels as a Marker of Breast Cancer Risk among BRCA1 Carriers. Cancers (Basel) 2021; 13:cancers13133345. [PMID: 34283078 PMCID: PMC8269342 DOI: 10.3390/cancers13133345] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/19/2021] [Revised: 06/25/2021] [Accepted: 06/29/2021] [Indexed: 11/16/2022] Open
Abstract
An important group of breast cancers is those associated with inherited susceptibility. In women, several predisposing mutations in genes involved in DNA repair have been discovered. Women with a germline pathogenic variant in BRCA1 have a lifetime cancer risk of 70%. As part of a larger prospective study on heavy metals, our aim was to investigate if blood arsenic levels are associated with breast cancer risk among women with inherited BRCA1 mutations. A total of 1084 participants with pathogenic variants in BRCA1 were enrolled in this study. Subjects were followed from 2011 to 2020 (mean follow-up time: 3.75 years). During that time, 90 cancers were diagnosed, including 67 breast and 10 ovarian cancers. The group was stratified into two categories (lower and higher blood As levels), divided at the median (<0.85 µg/L and ≥0.85 µg/L) As level among all unaffected participants. Cox proportional hazards models were used to model the association between As levels and cancer incidence. A high blood As level (≥0.85 µg/L) was associated with a significantly increased risk of developing breast cancer (HR = 2.05; 95%CI: 1.18-3.56; p = 0.01) and of any cancer (HR = 1.73; 95%CI: 1.09-2.74; p = 0.02). These findings suggest a possible role of environmental arsenic in the development of cancers among women with germline pathogenic variants in BRCA1.
Collapse
Affiliation(s)
- Wojciech Marciniak
- Department of Genetics and Pathology, Pomeranian Medical University, 71-252 Szczecin, Poland; (W.M.); (R.D.); (P.B.); (M.K.); (C.C.); (T.H.); (J.G.); (T.D.); (M.R.L.); (A.J.)
- Read-Gene SA, Westpomerania, 72-003 Grzepnica, Poland
| | - Tomáš Matoušek
- Institute of Analytical Chemistry of the Czech Academy of Sciences, 602 00 Brno, Czech Republic;
| | - Susan Domchek
- Basser Center for BRCA, Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA 19104, USA;
| | - Angelo Paradiso
- Center for Hereditary Tumors Research, Istituto Tumori Bari, Giovani Paolo II, IRCCS, 70124 Bari, Italy; (A.P.); (M.P.)
| | - Margherita Patruno
- Center for Hereditary Tumors Research, Istituto Tumori Bari, Giovani Paolo II, IRCCS, 70124 Bari, Italy; (A.P.); (M.P.)
| | - Arvids Irmejs
- Department of Surgery, Institute of Oncology, Riga Stradins University, Pauls Stradins Clinical University Hospital, LV-1007 Rīga, Latvia; (A.I.); (I.R.)
| | - Irita Roderte
- Department of Surgery, Institute of Oncology, Riga Stradins University, Pauls Stradins Clinical University Hospital, LV-1007 Rīga, Latvia; (A.I.); (I.R.)
| | - Róża Derkacz
- Department of Genetics and Pathology, Pomeranian Medical University, 71-252 Szczecin, Poland; (W.M.); (R.D.); (P.B.); (M.K.); (C.C.); (T.H.); (J.G.); (T.D.); (M.R.L.); (A.J.)
- Read-Gene SA, Westpomerania, 72-003 Grzepnica, Poland
| | - Piotr Baszuk
- Department of Genetics and Pathology, Pomeranian Medical University, 71-252 Szczecin, Poland; (W.M.); (R.D.); (P.B.); (M.K.); (C.C.); (T.H.); (J.G.); (T.D.); (M.R.L.); (A.J.)
- Read-Gene SA, Westpomerania, 72-003 Grzepnica, Poland
| | - Magdalena Kuświk
- Department of Genetics and Pathology, Pomeranian Medical University, 71-252 Szczecin, Poland; (W.M.); (R.D.); (P.B.); (M.K.); (C.C.); (T.H.); (J.G.); (T.D.); (M.R.L.); (A.J.)
| | - Cezary Cybulski
- Department of Genetics and Pathology, Pomeranian Medical University, 71-252 Szczecin, Poland; (W.M.); (R.D.); (P.B.); (M.K.); (C.C.); (T.H.); (J.G.); (T.D.); (M.R.L.); (A.J.)
- Read-Gene SA, Westpomerania, 72-003 Grzepnica, Poland
| | - Tomasz Huzarski
- Department of Genetics and Pathology, Pomeranian Medical University, 71-252 Szczecin, Poland; (W.M.); (R.D.); (P.B.); (M.K.); (C.C.); (T.H.); (J.G.); (T.D.); (M.R.L.); (A.J.)
- Read-Gene SA, Westpomerania, 72-003 Grzepnica, Poland
- Department of Clinical Genetics and Pathology, University of Zielona Góra, 65-046 Zielona Góra, Poland
| | - Jacek Gronwald
- Department of Genetics and Pathology, Pomeranian Medical University, 71-252 Szczecin, Poland; (W.M.); (R.D.); (P.B.); (M.K.); (C.C.); (T.H.); (J.G.); (T.D.); (M.R.L.); (A.J.)
- Read-Gene SA, Westpomerania, 72-003 Grzepnica, Poland
| | - Tadeusz Dębniak
- Department of Genetics and Pathology, Pomeranian Medical University, 71-252 Szczecin, Poland; (W.M.); (R.D.); (P.B.); (M.K.); (C.C.); (T.H.); (J.G.); (T.D.); (M.R.L.); (A.J.)
| | - Michał Falco
- West Pomeranian Oncology Center, Radiation Oncology Department, 71-730 Szczecin, Poland;
| | - Marcin R. Lener
- Department of Genetics and Pathology, Pomeranian Medical University, 71-252 Szczecin, Poland; (W.M.); (R.D.); (P.B.); (M.K.); (C.C.); (T.H.); (J.G.); (T.D.); (M.R.L.); (A.J.)
| | - Anna Jakubowska
- Department of Genetics and Pathology, Pomeranian Medical University, 71-252 Szczecin, Poland; (W.M.); (R.D.); (P.B.); (M.K.); (C.C.); (T.H.); (J.G.); (T.D.); (M.R.L.); (A.J.)
| | - Katherine Pullella
- Department of Nutritional Sciences, University of Toronto, Toronto, ON M5S 1A8, Canada;
| | - Joanne Kotsopoulos
- Dalla Lana School of Public Health, University of Toronto, Toronto, ON M5T 3M7, Canada;
| | - Steven Narod
- Familial Breast Cancer Research Unit, Women’s College Research Institute, Toronto, ON M5G 1N8, Canada;
| | - Jan Lubiński
- Department of Genetics and Pathology, Pomeranian Medical University, 71-252 Szczecin, Poland; (W.M.); (R.D.); (P.B.); (M.K.); (C.C.); (T.H.); (J.G.); (T.D.); (M.R.L.); (A.J.)
- Read-Gene SA, Westpomerania, 72-003 Grzepnica, Poland
- Correspondence: ; Tel.: +48-91-441-7250
| |
Collapse
|
4
|
Behrendt I, Eichner G, Fasshauer M. Association of Antioxidants Use with All-Cause and Cause-Specific Mortality: A Prospective Study of the UK Biobank. Antioxidants (Basel) 2020; 9:E1287. [PMID: 33339307 PMCID: PMC7766648 DOI: 10.3390/antiox9121287] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/19/2020] [Revised: 12/07/2020] [Accepted: 12/14/2020] [Indexed: 11/22/2022] Open
Abstract
Prospective studies and randomized controlled trials elucidating the impact of antioxidants supplementation on mortality risk are inconclusive. The present analysis determined association between regular antioxidants use and all-cause (primary objective), as well as cause-specific, mortality in 345,626 participants of the UK Biobank cohort using Cox proportional hazard models. All models were adjusted for confounders and multiple testing. Antioxidants users were defined as participants who indicated to regularly use at least one of the following: multivitamins, vitamin C, vitamin E, selenium, and zinc. Median age of antioxidants users (n = 101,159) and non-users (n = 244,467) at baseline was 57 years. During 3.9 million person-years and a median follow-up of 11.5 years, 19,491 deaths occurred. Antioxidants use was not significantly associated with all-cause, cancer, and non-cancer mortality including several cancer and non-cancer subtypes. Interestingly, mortality risk from respiratory disease was significantly 21% lower among antioxidants users as compared to non-users (hazard ratio: 0.79; 95% confidence interval: 0.67, 0.92). In conclusion, the present study findings do not support recommendations for antioxidants supplementation to prevent all-cause, cancer, or non-cancer mortality on a population level. The significant inverse association between antioxidants use and respiratory disease mortality needs further study.
Collapse
Affiliation(s)
- Inken Behrendt
- Institute of Nutritional Science, Justus-Liebig University of Giessen, 35390 Giessen, Germany;
| | - Gerrit Eichner
- Mathematical Institute, Justus-Liebig University of Giessen, 35392 Giessen, Germany;
| | - Mathias Fasshauer
- Institute of Nutritional Science, Justus-Liebig University of Giessen, 35390 Giessen, Germany;
- Department of Internal Medicine (Endocrinology, Nephrology, and Rheumatology), University of Leipzig, 04103 Leipzig, Germany
- Leipzig University Medical Center, IFB AdiposityDiseases, 04103 Leipzig, Germany
| |
Collapse
|
5
|
Sellami M, Bragazzi NL. Nutrigenomics and Breast Cancer: State-of-Art, Future Perspectives and Insights for Prevention. Nutrients 2020; 12:nu12020512. [PMID: 32085420 PMCID: PMC7071273 DOI: 10.3390/nu12020512] [Citation(s) in RCA: 14] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/26/2019] [Revised: 02/13/2020] [Accepted: 02/14/2020] [Indexed: 02/06/2023] Open
Abstract
Proper nutrition plays a major role in preventing diseases and, therefore, nutritional interventions constitute crucial strategies in the field of Public Health. Nutrigenomics and nutriproteomics are arising from the integration of nutritional, genomics and proteomics specialties in the era of postgenomics medicine. In particular, nutrigenomics and nutriproteomics focus on the interaction between nutrients and the human genome and proteome, respectively, providing insights into the role of diet in carcinogenesis. Further omics disciplines, like metabonomics, interactomics and microbiomics, are expected to provide a better understanding of nutrition and its underlying factors. These fields represent an unprecedented opportunity for the development of personalized diets in women at risk of developing breast cancer.
Collapse
Affiliation(s)
- Maha Sellami
- Sport Science Program (SSP), College of Arts and Sciences (CAS), Qatar University, Doha 2713, Qatar
- Correspondence: (M.S.); (N.L.B.)
| | - Nicola Luigi Bragazzi
- Postgraduate School of Public Health, Department of Health Sciences (DISSAL), University if Genoa, 16132 Genoa, Italy
- Laboratory for Industrial and Applied Mathematics (LIAM), Department of Mathematics and Statistics, York University, Toronto, ON M3J 1P3, Canada
- Correspondence: (M.S.); (N.L.B.)
| |
Collapse
|
6
|
Pettapiece-Phillips R, Kotlyar M, Chehade R, Salmena L, Narod SA, Akbari M, Jurisica I, Kotsopoulos J. Uninterrupted Sedentary Behavior Downregulates BRCA1 Gene Expression. Cancer Prev Res (Phila) 2015; 9:83-8. [DOI: 10.1158/1940-6207.capr-15-0291] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/27/2015] [Accepted: 10/21/2015] [Indexed: 11/16/2022]
|
7
|
Abstract
High serum levels of insulin-like growth factor I (IGF-I) are associated with an increased risk of sporadic breast cancer (BC). Furthermore, insulin and markers of insulin resistance, such as abdominal obesity, high blood glucose, high serum testosterone and metabolic syndrome, may affect both BC incidence and prognosis. We hypothesized that all these factors might be relevant also for hereditary BC, due to a deleterious mutation of BRCA genes. Epidemiological observation suggested that weight, energy intake (usually associated with higher bio-availability of growth factors) and physical activity may be relevant in BRCA mutation carriers. Mechanistic studies hypothesized a functional interaction between BRCA genes and the IGF-I system. We have provided some evidence that high serum levels of IGF-I are associated with a significantly increased penetrance. We are recruiting a larger cohort of BRCA mutation carriers in order to test potential modulators of penetrance and prognosis. Within this cohort, we have planned a randomized controlled trial to test whether moderate calorie and protein restriction, together with physical activity, decrease IGF-I. Eligible study subjects are women with or without BC, aged 18-70, with a proven deleterious BRCA mutation, and without metastases. All the women will receive recommendations for the dietary prevention of cancer. The women will be then randomized into an active life-style intervention group and into a control group that will receive only the baseline recommendations. We expect to significantly reduce IGF-I in the intervention group. This trial and the subsequent cohort follow-up might open up primary prevention options for genetic BC.
Collapse
|
8
|
Pettapiece-Phillips R, Narod SA, Kotsopoulos J. The role of body size and physical activity on the risk of breast cancer in BRCA mutation carriers. Cancer Causes Control 2015; 26:333-44. [PMID: 25579073 DOI: 10.1007/s10552-014-0521-0] [Citation(s) in RCA: 30] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/14/2014] [Accepted: 12/23/2014] [Indexed: 01/18/2023]
Abstract
Women who inherit a BRCA mutation face a high lifetime risk of developing breast cancer. Given the high penetrance of these mutations, prevention is of extreme importance. Here, we review the literature regarding the role of body size and of physical activity in the context of BRCA-associated breast cancer. There is some evidence to support a protective role of a healthy body size and of regular physical activity among mutation carriers, particularly during adolescence or early adulthood. Factors which increase the physiologic expression of the normal copy of the BRCA1 or BRCA2 gene and thereby normalize protein levels, contribute to stem cell homeostasis, and/or affect hormone levels, might mitigate the effects of an inherited BRCA mutation. Preliminary evidence from one in vivo study and from one epidemiologic report suggests that an increase in BRCA1 mRNA expression occurs with increasing levels of physical activity. The prospect of changing lifestyle for the purpose of preventing breast cancer in high-risk women, complemented by mechanistic evidence, warrants evaluation in large-scale prospective studies.
Collapse
Affiliation(s)
- Rachael Pettapiece-Phillips
- Women's College Research Institute, Women's College Hospital, 790 Bay Street, 7th Floor, Toronto, ON, M5G 1N8, Canada
| | | | | |
Collapse
|
9
|
BRCA1 mRNA levels following a 4-6-week intervention with oral 3,3'-diindolylmethane. Br J Cancer 2014; 111:1269-74. [PMID: 25025957 PMCID: PMC4183839 DOI: 10.1038/bjc.2014.391] [Citation(s) in RCA: 19] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/14/2014] [Revised: 05/26/2014] [Accepted: 06/18/2014] [Indexed: 12/19/2022] Open
Abstract
Background: Haploinsufficiency may contribute to the development of breast cancer among women with a BRCA1 mutation. Thus, interventions that enhance BRCA1 expression may represent avenues for prevention. Studies have shown that 3,3′-diindolylmethane (DIM) can upregulate BRCA1 expression in breast cancer cells. This has yet to be demonstrated in vivo. Methods: We conducted a study to evaluate the ability of oral DIM to upregulate BRCA1 mRNA expression in white blood cells. A total of 18 women were enroled in the study, including 13 BRCA1 mutation carriers who received 300 mg per day of Rx Balance BioResponse DIM for 4–6 weeks (intervention group) and 5 BRCA1 mutation carriers who did not take DIM (control group). BRCA1 mRNA expression was assessed at baseline and at 4–6 weeks by real-time, quantitative PCR and the relative change in BRCA1 mRNA expression (that is, 2−ΔΔCT) was calculated. Results: The relative change in BRCA1 mRNA expression among women in the intervention group achieved borderline significance (P paired t-test=0.05). In the intervention group, BRCA1 mRNA expression increased in 10 of the participants, decreased in 2 and remained unchanged in 1 of the participants following DIM intervention (P sign test=0.02). On average, women in the intervention group experienced a 34% increase in BRCA1 mRNA expression (range −24 to 194%). There was no significant difference in the relative change in BRCA1 mRNA expression among women in the control group (P paired t-test=0.45). Conclusions: Under the tested conditions, oral DIM was associated with an increase in BRCA1 mRNA expression in women with a BRCA1 mutation. The possibility of mitigating the effect of an inherited deleterious BRCA1 mutation by increasing the physiologic expression of the gene and normalising protein levels represents a clinically important paradigm shift in the prevention strategies available to these high-risk women. Future studies with a larger sample size and higher doses of DIM are warranted.
Collapse
|
10
|
Kotsopoulos J, Kim YI, Narod SA. Folate and breast cancer: what about high-risk women? Cancer Causes Control 2012; 23:1405-20. [DOI: 10.1007/s10552-012-0022-y] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/03/2012] [Accepted: 06/20/2012] [Indexed: 12/31/2022]
|
11
|
Plasma micronutrients, trace elements, and breast cancer in BRCA1 mutation carriers: an exploratory study. Cancer Causes Control 2012; 23:1065-74. [PMID: 22576580 DOI: 10.1007/s10552-012-9975-0] [Citation(s) in RCA: 21] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/30/2011] [Accepted: 04/16/2012] [Indexed: 12/13/2022]
Abstract
PURPOSE Few studies have evaluated the role of micronutrients or trace elements in breast cancer development among BRCA1 mutation carriers. To investigate a possible role of dietary and environmental exposures on cancer risk, we undertook an exploratory study, using a matched case-control design (n = 48 cases and 96 controls), to evaluate the relationships between plasma levels of 14 micronutrients and breast cancer risk among BRCA1 mutation carriers in Poland. METHODS We estimated the univariate odds ratios (OR) and 95 % confidence intervals (CI) for breast cancer associated with plasma levels for each of 14 micronutrients. RESULTS Of the 14 analytes quantified, significant differences between cases and controls were seen for two (iron and retinol; p = 0.009 and p = 0.03, respectively). Women in the highest tertile of plasma iron had a 57 % lower risk, compared with those in the lowest quartile (OR = 0.43; 95 % CI 0.18-1.04; p for trend = 0.06). Increasing antimony levels were associated with an increased risk of breast cancer (p for trend = 0.05). Women in the highest tertile had a 2.43-fold increase in breast cancer risk compared with women in the lowest tertile (OR = 2.43; 95 % CI 1.00-5.91). CONCLUSIONS This study provides some preliminary evidence regarding a role of diet, specifically iron and antimony, in the etiology of BRCA1-associated breast cancer. Prospective studies are necessary to confirm these findings.
Collapse
|
12
|
Pasanisi P, Bruno E, Venturelli E, Manoukian S, Barile M, Peissel B, De Giacomi C, Bonanni B, Berrino J, Berrino F. Serum levels of IGF-I and BRCA penetrance: a case control study in breast cancer families. Fam Cancer 2012; 10:521-8. [PMID: 21455766 DOI: 10.1007/s10689-011-9437-y] [Citation(s) in RCA: 25] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/19/2022]
Abstract
High serum levels of insulin-like growth factor I (IGF-I) are associated with an increased risk of sporadic breast cancer (BC). The aim of the present work is to evaluate the association between IGF-I and hereditary BC risk, using a case-control approach. The work represents an "ad interim" cross-sectional analysis of an ongoing study with a prospective design whose aim is to recruit a cohort of women belonging to high genetic risk families to test potential modulators of penetrance and prognosis. The odd of exposure to high serum IGF-I levels among women with a previous diagnosis of BC ("cases") was compared with the odd among unaffected "controls". The odds ratio (OR) and 95% confidence intervals (CIs) were estimated by unconditional logistic regression, controlling for confounders. We analysed 308 women (209 cases and 99 controls) at high genetic risk of BC. The adjusted OR of BC for the upper tertile of serum IGF-I versus the lowest one was 3.5 (95%CI 1.4-8.8). Excluding from the analysis 64 women under current Tamoxifen or GnRH analogues treatment, the adjusted OR of BC became 3.7 (95%CI 1.4-9.9). The association became stronger restricting the analysis to the 161 women (97 cases and 64 controls) with a proven BRCA mutation. If confirmed by a prospective approach, the association between IGF-I and familial BC will open further options for reducing BC risk in susceptible women.
Collapse
Affiliation(s)
- Patrizia Pasanisi
- Etiological and Preventive Epidemiology Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.
| | | | | | | | | | | | | | | | | | | |
Collapse
|
13
|
Palmquist AEL, Upton R, Lee S, Panter AT, Hadley DW, Koehly LM. Beliefs about cancer and diet among those considering genetic testing for colon cancer. JOURNAL OF NUTRITION EDUCATION AND BEHAVIOR 2011; 43:150-6. [PMID: 21296025 PMCID: PMC3090483 DOI: 10.1016/j.jneb.2009.12.009] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Received: 07/20/2009] [Revised: 12/15/2009] [Accepted: 12/18/2009] [Indexed: 05/30/2023]
Abstract
OBJECTIVE To assess beliefs about the role of diet in cancer prevention among individuals considering genetic testing for Lynch Syndrome. DESIGN Family-centered, cascade recruitment; baseline assessment of a longitudinal study. SETTING Clinical research setting. PARTICIPANTS Participants were 390 persons, ages 18 and older, including persons with a Lynch Syndrome-associated cancer and suspected of carrying a disease causing mutation, and relatives at risk for inheriting a previously identified mutation. MAIN OUTCOME MEASURES Assess clustering of beliefs about the role of diet in cancer prevention and predictors of class membership. ANALYSIS Confirmatory factor analysis; 2-class factor mixture model with binary indicators; multilevel regression analyses, individuals nested within families. RESULTS Women endorsed a relationship between diet and cancer prevention more often than men (P < .01). A 2-class model was used where Class 1 indicated less likely to link cancer to diet, and Class 2 indicated more likely. Factors associated with increased odds of membership in Class 1 expressed belief that nothing can prevent cancer (P < .01) and fate attribution (P < .01); Class 2 mentioned personal cancer history (P < .05) and genetic knowledge (P < .01). CONCLUSIONS AND IMPLICATIONS Identifying factors associated with a belief in cancer prevention through dietary behaviors can inform targeted interventions.
Collapse
|
14
|
Dietary phenethyl isothiocyanate alters gene expression in human breast cancer cells. EVIDENCE-BASED COMPLEMENTARY AND ALTERNATIVE MEDICINE 2010; 2011. [PMID: 20953429 PMCID: PMC2952307 DOI: 10.1155/2011/462525] [Citation(s) in RCA: 26] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 06/04/2009] [Revised: 11/05/2009] [Accepted: 08/31/2010] [Indexed: 11/18/2022]
Abstract
Phenethyl isothiocyanate (PEITC), a component in cruciferous vegetables, can block chemical carcinogenesis in animal models. Our objective was to determine the effect of treatment with PEITC on gene expression changes in MCF-7 human breast cancer cells in order to evaluate potential mechanisms involved in its chemopreventive effects. MCF-7 cells were treated for 48 hours with either PEITC (3 μM) or the vehicle. Total RNA was extracted from cell membrane preparations, and labeled cDNA's representing the mRNA pool were reverse-transcribed directly from total RNA isolated for use in the microarray hybridizations. Two specific human GE Array Kits (Superarray Inc.) that both contain 23 marker genes, related to signal transduction pathways or cancer/tumor suppression, plus 2 housekeeping genes (β-actin and GAPDH), were utilized. Arrays from treated and control cells (n = 4 per group) were evaluated using a Student's t-test. Gene expression was significantly induced for tumor protein p53 (p53), cyclin-dependent kinase inhibitor 1C (p57 Kip2), breast cancer Type 2 early onset (BRCA2), cAMP responsive element binding protein 2 (ATF-2), interleukin 2 (IL-2), heat shock 27 KD protein (hsp27), and CYP19 (aromatase). Induction of p57 Kip2, p53, BRCA2, IL-2, and ATF-2 would be expected to decrease cellular proliferation and increase tumor suppression and/or apoptosis. PEITC treatment produced significant alterations in some genes involved in tumor suppression and cellular proliferation/apoptosis that may be important in explaining the chemopreventive effects of PEITC.
Collapse
|
15
|
Karimi-Busheri F, Rasouli-Nia A, Mackey JR, Weinfeld M. Senescence evasion by MCF-7 human breast tumor-initiating cells. Breast Cancer Res 2010; 12:R31. [PMID: 20525204 PMCID: PMC2917024 DOI: 10.1186/bcr2583] [Citation(s) in RCA: 82] [Impact Index Per Article: 5.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/06/2009] [Revised: 05/13/2010] [Accepted: 06/02/2010] [Indexed: 12/20/2022] Open
Abstract
Introduction A subpopulation of cancer cells, tumor-initiating cells, is believed to be the driving force behind tumorigenesis and resistance to radiation and chemotherapy. The persistence of tumor-initiating cells may depend on altered regulation of DNA damage and checkpoint proteins, as well as a reduced propensity to undergo apoptosis or senescence. Methods To test this hypothesis, we isolated CD24-/low/CD44+ tumor-initiating cells (as mammospheres) from MCF-7 breast cancer cells grown in adherent monolayer culture, and carried out a comprehensive comparison of cell death and DNA damage response pathways prior to and after exposure to ionizing radiation in mammospheres and monolayer MCF-7 cells. Single and double-strand break repair was measured by single-cell gel electrophoresis. The latter was also examined by phosphorylation of histone H2AX and formation of 53BP1 and Rad51 foci. Apoptosis was quantified by flow-cytometric analysis of annexin V-binding and senescence was analyzed on the basis of cellular β-galactosidase activity. We employed the telomeric repeat amplification protocol to quantify telomerase activity. Expression of key DNA repair and cell cycle regulatory proteins was detected and quantified by western blot analysis. Results Our data demonstrate that in comparison to the bulk population of MCF-7 cells (predominantly CD24+/CD44+), the MCF-7 mammosphere cells benefit from a multifaceted approach to cellular protection relative to that seen in monolayer cells, including a reduced level of reactive oxygen species, a more active DNA single-strand break repair (SSBR) pathway, possibly due to a higher level of expression of the key SSBR protein, human AP endonuclease 1 (Ape1), and a significantly reduced propensity to undergo senescence as a result of increased telomerase activity and a low level of p21 protein expression. No significant difference was seen in the rates of double-strand break repair (DSBR) between the two cell types, but DSBR in mammospheres appears to by-pass the need for H2AX phosphorylation. Conclusions Enhanced survival of MCF-7 tumor-initiating cells in response to ionizing radiation is primarily dependent on an inherent down-regulation of the senescence pathway. Since MCF-7 cells are representative of cancer cells that do not readily undergo apoptosis, consideration of senescence pathways may play a role in targeting stem cells from such tumors.
Collapse
Affiliation(s)
- Feridoun Karimi-Busheri
- Department of Oncology, University of Alberta and Department of Experimental Oncology, Cross Cancer Institute, 11560 University Avenue, Edmonton, Alberta, Canada.
| | | | | | | |
Collapse
|
16
|
Kotsopoulos J, Chen Z, Vallis KA, Poll A, Ghadirian P, Kennedy G, Ainsworth P, Narod SA. Toenail selenium status and DNA repair capacity among female BRCA1 mutation carriers. Cancer Causes Control 2010; 21:679-87. [DOI: 10.1007/s10552-009-9495-8] [Citation(s) in RCA: 20] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/20/2009] [Accepted: 12/21/2009] [Indexed: 12/21/2022]
|
17
|
Pasanisi P, Hédelin G, Berrino J, Chang-Claude J, Hermann S, Steel M, Haites N, Hart J, Peled R, Gafà L, Leggio L, Traina A, Amodio R, Primic-Zakelj M, Zadnik V, Veidebaum T, Tekkel M, Berrino F. Oral Contraceptive Use and BRCA Penetrance: A Case-Only Study. Cancer Epidemiol Biomarkers Prev 2009; 18:2107-13. [DOI: 10.1158/1055-9965.epi-09-0024] [Citation(s) in RCA: 16] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022] Open
|
18
|
Health behaviors among Ashkenazi Jewish individuals receiving counseling for BRCA1 and BRCA2 mutations. Fam Cancer 2009; 8:241-50. [DOI: 10.1007/s10689-009-9235-y] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/26/2008] [Accepted: 01/09/2009] [Indexed: 12/19/2022]
|
19
|
O'Neill SC, Kaufman E, DeMarco T, Peshkin BN, McKenna K, Shelby R, Valdimarsdottir H, Rispoli J, Schwartz MD. Changes in Diet and Physical Activity FollowingBRCA1/2Testing. J Psychosoc Oncol 2008; 26:63-80. [DOI: 10.1080/07347330802116051] [Citation(s) in RCA: 14] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/19/2022]
|
20
|
Tercyak KP, Peshkin BN, Demarco TA, Patenaude AF, Schneider KA, Garber JE, Valdimarsdottir HB, Schwartz MD. Information needs of mothers regarding communicating BRCA1/2 cancer genetic test results to their children. ACTA ACUST UNITED AC 2008; 11:249-55. [PMID: 17949286 DOI: 10.1089/gte.2006.0534] [Citation(s) in RCA: 47] [Impact Index Per Article: 2.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022]
Abstract
Mothers who participate in genetic testing for hereditary breast/ovarian cancer risk must decide if, when, and how to ultimately share their BRCA1 and BRCA2 (BRCA1/2) test results with their minor-age children. One of the primary aides for mothers in making this decision is cancer genetic counseling. However, counseling is limited in how well it can educate mothers about such decisions without the availability of resources that are specific to family communication and genetic testing per se. In an effort to fill this gap and identify mothers most likely to benefit from such resources, surveys were conducted with 187 mothers undergoing BRCA1/2 testing who had children 8-21 years old. Data were collected weeks after genetic testing but prior to mothers' learning of their test results; quantitative assessments of informational resource needs (i.e., speaking with previous BRCA1/2 testing participants who are parents regarding their experiences, reading educational literature about options and what to expect, speaking with a family counselor, attending a family support group, and self-nominated other resources), testing motivations, decision making vigilance, and decisional conflict regarding communicating test results to children were included. Mothers' most-to-least frequently cited information resource needs were: literature (93.4%), family counseling (85.8%), prior participants (79.0%), support groups (53.9%), and other (28.9%; e.g., pediatricians and psychologists). Seventy-eight percent of mothers were interested in accessing three or more resources. In multivariate regression analyses, testing motivations (beta = 0.35, p = 0.03), decision-making vigilance (beta = 0.16, p = 0.00), and decisional conflict (beta = 0.10, p = 0.00) were associated with mothers' need level; mothers with a greater interest in testing to learn about their children's risks, those with more vigilant decision-making styles, and those with higher decisional conflict had the greatest need. In conjunction with enhanced genetic counseling focusing on family disclosure, educational literature, and psychosocial support may promote improved outcomes.
Collapse
Affiliation(s)
- Kenneth P Tercyak
- Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, Washington, DC 20007-2401, USA.
| | | | | | | | | | | | | | | |
Collapse
|
21
|
Abstract
Este artigo discute as possibilidades de proteção contra o desenvolvimento do câncer, proporcionadas por carotenóides provenientes da alimentação, com base em uma revisão da literatura. Os carotenóides têm demonstrado uma ação protetora contra a carcinogênese, tanto em estudos in vitro como in vivo, com animais e humanos. Entre eles, a beta-criptoxantina, a fucoxantina, a astaxantina, a capsantina, a crocetina e o fitoeno, têm sido pouco explorados, e a literatura ainda se mostra extremamente limitada e pouco conclusiva. Estudos experimentais com humanos demonstraram não haver efeito, ou efeito reverso, do beta-caroteno, no entanto, não incluíram anteriormente variáveis intervenientes e interativas que deveriam ter sido controladas. A partir da evidência científica, baseada em estudos epidemiológicos e ensaios experimentais recentes, e da elucidação dos mecanismos de atuação de fitoquímicos relacionados à maior proteção contra o câncer, conclui-se que a alimentação rica em carotenóides provenientes das frutas, legumes e verduras, representa um possível fator de proteção contra o desenvolvimento do câncer.
Collapse
|
22
|
Israeli ‘cancer shift’ over heart disease mortality may be led by greater risk in women with high intake of n-6 fatty acids. Eur J Cancer Prev 2007; 16:486-94. [DOI: 10.1097/cej.0b013e3280145b6d] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
23
|
McKinnon W, Naud S, Ashikaga T, Colletti R, Wood M. Results of an intervention for individuals and families with BRCA mutations: a model for providing medical updates and psychosocial support following genetic testing. J Genet Couns 2007; 16:433-56. [PMID: 17594133 DOI: 10.1007/s10897-006-9078-8] [Citation(s) in RCA: 43] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/13/2006] [Accepted: 11/16/2006] [Indexed: 01/07/2023]
Abstract
: Providing medical management updates and long-term support to families with hereditary cancer syndromes in rural areas is a challenge. To address this, we designed a one-day retreat for BRCA1/2 carriers in our region. The retreat included educational updates about medical management, genetic privacy and discrimination, and addressed psychological and family issues. Evaluations completed at the conclusion of the retreat were overwhelmingly positive with requests for a similar event in the future. The impact of this retreat on a variety of health behaviors was assessed. Eligible participants completed questionnaires before and 6 months after the retreat. Questionnaires focused on lifestyle, cancer screening and prevention practices, psychological history and distress, decision-making regarding genetic testing, and family communication issues. For individuals who completed both the pre and post retreat questionnaires, one-half made lifestyle changes and nearly two-thirds increased cancer screening, initiated chemoprevention, completed or planned to complete preventative surgery in the future. We conclude that this type of forum provides a valuable opportunity for BRCA carriers and their families to receive updated medical information, share personal experiences, provide and receive support, as well as change health behaviors.
Collapse
Affiliation(s)
- Wendy McKinnon
- Department of Pediatrics, University of Vermont College of Medicine, Burlington, VT 05401, USA.
| | | | | | | | | |
Collapse
|
24
|
Cade JE, Burley VJ, Greenwood DC. Dietary fibre and risk of breast cancer in the UK Women's Cohort Study. Int J Epidemiol 2007; 36:431-8. [PMID: 17251246 DOI: 10.1093/ije/dyl295] [Citation(s) in RCA: 89] [Impact Index Per Article: 5.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Abstract
BACKGROUND Reports of relationships between dietary fibre intake and breast cancer have been inconsistent. Previous cohort studies have been limited by a narrow range of intakes. METHODS Women who developed invasive breast cancer, 350 post-menopausally and 257 pre-menopausally, during 240,959 person-years of follow-up in the UK Women's Cohort Study (UKWCS) were studied. This cohort has 35,792 subjects with a wide range of exposure to dietary fibre with intakes of total fibre in the lowest quintile of <20 g/day up to >30 g/day in the top quintile. Fibre and breast cancer relationships were explored using Cox regression modelling adjusted for measurement error. Effects of fibre, adjusting for confounders were examined for pre- and post-menopausal women separately. RESULTS In pre-menopausal, but not post-menopausal women a statistically significant inverse relationship was found between total fibre intake and risk of breast cancer (P for trend = 0.01). The top quintile of fibre intake was associated with a hazard ratio of 0.48 [95% confidence interval (CI) 0.24-0.96] compared with the lowest quintile. Pre-menopausally, fibre from cereals was inversely associated with risk of breast cancer (P for trend = 0.05) and fibre from fruit had a borderline inverse relationship (P for trend = 0.09). A further model including dietary folate strengthened the significance of the inverse relationship between total fibre and pre-menopausal breast cancer. CONCLUSIONS These findings suggest that in pre-menopausal women, total fibre is protective against breast cancer; in particular, fibre from cereals and possibly fruit.
Collapse
|
25
|
Kotsopoulos J, Chen Z, Vallis KA, Poll A, Ainsworth P, Narod SA. DNA repair capacity as a possible biomarker of breast cancer risk in female BRCA1 mutation carriers. Br J Cancer 2007; 96:118-25. [PMID: 17213827 PMCID: PMC2360222 DOI: 10.1038/sj.bjc.6603528] [Citation(s) in RCA: 35] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/17/2006] [Revised: 11/10/2006] [Accepted: 11/14/2006] [Indexed: 11/23/2022] Open
Abstract
The BRCA1 gene product helps to maintain genomic integrity through its participation in the cellular response to DNA damage: specifically, the repair of double-stranded DNA breaks. An impaired cellular response to DNA damage is a plausible mechanism whereby BRCA1 mutation carriers are at increased risk of breast cancer. Hence, an individual's capacity to repair DNA may serve as a useful biomarker of breast cancer risk. The overall aim of the current study was to identify a biomarker of DNA repair capacity that could distinguish between BRCA1 mutation carriers and non-carriers. DNA repair capacity was assessed using three validated assays: the single-cell alkaline gel electrophoresis (comet) assay, the micronucleus test, and the enumeration of gamma-H2AX nuclear foci. DNA repair capacity of peripheral blood lymphocytes from 25 cancer-free female heterozygous BRCA1 mutation carriers and 25 non-carrier controls was assessed at baseline and following cell exposure to gamma-irradiation (2 Gy). We found no significant differences in the mean tail moment, in the number of micronuclei or in the number of gamma-H2AX nuclear foci between the carriers and non-carriers at baseline, and following gamma-irradiation. These data suggest that these assays are not likely to be useful in the identification of women at a high risk for breast cancer.
Collapse
Affiliation(s)
- J Kotsopoulos
- Centre for Research in Women's Health, Women's College Hospital, 790 Bay Street, Room 750, 7th Floor, Toronto, Ontario, Canada M5G 1N8
- Department of Nutritional Sciences, Faculty of Medicine, University of Toronto, FitzGerald Building, 150 College Street, Toronto, Ontario, Canada M5S 3E2
| | - Z Chen
- Department of Radiation Oncology, Princess Margaret Hospital, 610 University Ave, Toronto, Ontario, Canada M5G 2M9
| | - K A Vallis
- Department of Radiation Oncology, Princess Margaret Hospital, 610 University Ave, Toronto, Ontario, Canada M5G 2M9
| | - A Poll
- Centre for Research in Women's Health, Women's College Hospital, 790 Bay Street, Room 750, 7th Floor, Toronto, Ontario, Canada M5G 1N8
| | - P Ainsworth
- London Health Sciences Center, Molecular Diagnostic Laboratory, Room E3-304, Westminster Tower, 800 Commissioner's Road East, London, Ontario, Canada N6A 4G5
| | - S A Narod
- Centre for Research in Women's Health, Women's College Hospital, 790 Bay Street, Room 750, 7th Floor, Toronto, Ontario, Canada M5G 1N8
| |
Collapse
|
26
|
Abstract
Lifestyle behaviors have not been adequately addressed as potential cancer risk-reduction strategies in women with BRCA1 or BRCA2 genetic mutations. The aims of this qualitative pilot study were to explore current lifestyle practices among these women and to assess perceptions regarding risk as well as perceived benefits and perceived barriers to engage in healthy behaviors. Qualitative descriptive methodology was used with research questions derived from key Health Belief Model concepts. Interviews were conducted with 10 women recruited through a cancer genetics clinic. Interviews were tape-recorded and transcribed for content analysis of common themes and patterns. All of the participants expressed that they were at high risk for cancer; however, 5 of the women had prophylactic surgery, which decreased their sense of risk. Most women made some healthy behavior change as a result of their elevated risk awareness. Perceived benefits to healthy lifestyles included increased energy and improved mood. Perceived barriers were related to the expense and inconvenience of preparing healthy meals and lack of time to exercise. The findings reveal that there is a need for nursing interventions that may improve education and enhance motivation regarding potential lifestyle risk-reduction behaviors in women with a genetic predisposition for breast and ovarian cancer.
Collapse
Affiliation(s)
- Denise Spector
- School of Nursing, University of North Carolina at Chapel Hill, Chapel Hill, NC 27516, USA.
| |
Collapse
|
27
|
Narod SA. Regarding the use of tamoxifen post-oophorectomy to prevent hereditary breast cancer. Hered Cancer Clin Pract 2006; 4:167-8. [PMID: 20223019 PMCID: PMC2837304 DOI: 10.1186/1897-4287-4-4-167] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/05/2006] [Accepted: 12/05/2006] [Indexed: 11/10/2022] Open
Affiliation(s)
- Steven A Narod
- Centre for Research on Women's Health, 790 Bay Street, Toronto, Ontario, Canada M5G 1N8.
| |
Collapse
|
28
|
Abstract
Mutations in the BRCA1 and BRCA2 genes confer a high lifetime risk of breast and ovarian cancer. The risk varies from individual to individual, and it appears that the risk has increased in recent generations. These observations imply that non-genetic factors may modify the inherited risk. To date, the factors that appear most strongly to modify the risk include reproductive histories and exogenous hormones. Oral contraceptives are associated with a profound reduction in the risk of ovarian cancer, and with little or no increase in the risk of breast cancer. Other modifying factors include age of menarche, parity, breastfeeding and oophorectomy. The effect of parity is different in BRCA1 and BRCA2 carriers. Multiparity appears to be protective in BRCA1 carriers, but is associated with an increase in risk in BRCA2 carriers. Oophorectomy has been associated with reductions in both the risk of breast and ovarian cancer. Knowledge of these risk factors will be useful for managing risk and for developing prevention strategies.
Collapse
Affiliation(s)
- S A Narod
- The Centre for Research in Women's Health, Women's College Hospital, University of Toronto, Toronto, Canada.
| |
Collapse
|
29
|
Cousineau I, Abaji C, Belmaaza A. BRCA1 regulates RAD51 function in response to DNA damage and suppresses spontaneous sister chromatid replication slippage: implications for sister chromatid cohesion, genome stability, and carcinogenesis. Cancer Res 2006; 65:11384-91. [PMID: 16357146 DOI: 10.1158/0008-5472.can-05-2156] [Citation(s) in RCA: 77] [Impact Index Per Article: 4.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
The breast/ovarian cancer susceptibility proteins BRCA1 and BRCA2 maintain genome stability, at least in part, through a functional role in DNA damage repair. They both colocalize with RAD51 at sites of DNA damage/replication and activate RAD51-mediated homologous recombination repair of DNA double-strand breaks (DSB). Whereas BRCA2 interacts directly with and regulates RAD51, the role of BRCA1 in this process is unclear. However, BRCA1 may regulate RAD51 in response to DNA damage or through its ability to interact with and regulate MRE11/RAD50/NBS1 (MRN) during the processing of DSBs into single-strand DNA (ssDNA) ends, prerequisite substrates for RAD51, or both. To test these hypotheses, we measured the effect of BRCA1 on the competition between RAD51-mediated homologous recombination (gene conversion and crossover) versus RAD51-independent homologous recombination [single-strand annealing (SSA)] for ssDNA at a site-specific chromosomal DSB within a DNA repeat, a substrate for both homologous recombination pathways. Expression of wild-type BRCA1 in BRCA1-deficient human recombination reporter cell lines promoted both gene conversion and SSA but greatly enhanced gene conversion. In addition, BRCA1 also suppressed both spontaneous gene conversion and deletion events, which can arise from either crossover or sister chromatid replication slippage (SCRS), a RAD51-independent process. BRCA1 does not seem to block crossover. From these results, we conclude that (a) BRCA1 regulates RAD51 function in response to the type of DNA damage and (b) BRCA1 suppresses SCRS, suggesting a role for this protein in sister chromatid cohesion/alignment. Loss of such control in response to estrogen-induced DNA damage after BRCA1 inactivation may be a key initial event that triggers genome instability and carcinogenesis.
Collapse
Affiliation(s)
- Isabelle Cousineau
- Molecular Biology Program and Department of Biochemistry, Université de Montréal, Quebec, Canada
| | | | | |
Collapse
|
30
|
Nkondjock A, Ghadirian P, Kotsopoulos J, Lubinski J, Lynch H, Kim-Sing C, Horsman D, Rosen B, Isaacs C, Weber B, Foulkes W, Ainsworth P, Tung N, Eisen A, Friedman E, Eng C, Sun P, Narod SA. Coffee consumption and breast cancer risk amongBRCA1 andBRCA2 mutation carriers. Int J Cancer 2005; 118:103-7. [PMID: 16032702 DOI: 10.1002/ijc.21296] [Citation(s) in RCA: 62] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
Abstract
Although there are several plausible biologic mechanisms whereby coffee consumption might influence the risk of breast cancer, epidemiologic evidence is limited. We assessed the association between coffee consumption and breast cancer risk among high-risk women who carry BRCA mutations. We performed a matched case-control analysis on 1,690 women with a BRCA1 or BRCA2 mutation from 40 centers in 4 countries. Average lifetime coffee consumption was estimated via a self-administered questionnaire. Odds ratios (ORs) and 95% confidence intervals (CIs) were estimated using conditional logistic regression. After adjustment for potential confounders, the ORs for breast cancer in BRCA carriers who habitually drank 0, 1-3, 4-5 and 6 or more cups of coffee were 1.00, 0.90 (95% CI 0.72-1.12), 0.75 (95% CI 0.47-1.19) and 0.31 (95% CI 0.13-0.71; p-trend = 0.02). The effect was limited to the consumption of caffeinated coffee. These results suggest that among women with BRCA gene mutation, coffee consumption is unlikely to be harmful and that high levels of consumption may in fact be related to reduced breast cancer risk.
Collapse
Affiliation(s)
- André Nkondjock
- Epidemiology Research Unit, Research Centre, Centre Hospitalier de 'Universitaire de Montréal, CHUM Hôtel-Dieu, Montréal, Canada
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|